SALT LAKE CITY, April 09, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc (MYGN). (NASDAQ: MYGN), a leader in genetic testing and precision medicine, revealed results from a multi-year, real-world study ...
On Monday, in its earnings release, Myriad Genetics Inc. (NASDAQ:MYGN) said Unitedhealth Group Inc’s (NYSE:UNH) UnitedHealthcare will stop covering multi-gene panel pharmacogenetic testing, including ...
In recent years, Myriad's economic profitability has fallen well below its cost of capital and its returns have been hampered due to a shift in its hereditary testing products and investment in new ...
SALT LAKE CITY, April 21, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc (MYGN). (NASDAQ: MYGN), a leader in molecular diagnostics testing and precision medicine, today announced that the Journal of ...
GeneSight is a pharmacogenomic test that analyzes how an individual’s genetic variations impact his or her response to medication. From 2019 through 2020, GeneSight set new records for volume and ...
Insurance covers some genetic tests, such as BRCA tests for breast cancer, if you meet certain requirements. Find Cheap Health Insurance Quotes in Your Area But there are about 70,000 different ...
Medicare Part B covers various genetic tests for diagnosing genetic conditions, identifying cancer risks, and predicting medication responses if a doctor deems them medically necessary. The cost of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback